Generalized epilepsy with febrile seizures plus
Generalized epilepsy with febrile seizures plus (GEFS+) is a genetic disorder characterized by a spectrum of epileptic seizures that begin in childhood. This condition is part of a group of disorders known as the genetic epilepsy with febrile seizures plus (GEFS+) spectrum.
Clinical Features
Individuals with GEFS+ experience a variety of seizure types, including febrile seizures, which are seizures associated with fever. These seizures typically occur in children between the ages of 6 months and 5 years. In addition to febrile seizures, affected individuals may experience other types of seizures, such as absence seizures, myoclonic seizures, and tonic-clonic seizures.
Genetic Basis
GEFS+ is caused by mutations in several genes, most commonly the SCN1A gene, which encodes a subunit of a sodium channel involved in the generation and propagation of action potentials in neurons. Other genes associated with GEFS+ include SCN1B, SCN2A, and GABRG2. These genetic mutations affect the normal function of ion channels, leading to increased neuronal excitability and seizures.
Diagnosis
The diagnosis of GEFS+ is based on clinical evaluation, family history, and electroencephalogram (EEG) findings. Genetic testing can confirm the diagnosis by identifying mutations in the associated genes. An EEG may show generalized spike-and-wave discharges, which are characteristic of generalized epilepsy.
Treatment
Treatment for GEFS+ typically involves the use of antiepileptic drugs (AEDs) to control seizures. The choice of medication depends on the specific type of seizures experienced by the individual. Commonly used AEDs include valproate, lamotrigine, and topiramate. In some cases, supportive care and lifestyle modifications, such as avoiding seizure triggers, may also be recommended.
Prognosis
The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity and frequency of seizures can also vary widely among affected individuals.
See Also
References
External Links
Generalized epilepsy with febrile seizures plus
-
Sodium channel beta GEFS+
-
GABRG2 GEFS+
-
SCN2A GEFS+
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian